Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of RZ358 in congenital hyperinsulinism
MOH_2023-11-23_013070Phase 3Not yet recruiting
- Sponsor
- Rezolute, Inc.
- Start
- Sep 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ersodetug in congenital hyperinsulinism (HI) (4 arms), sponsored by Rezolute, Inc. Planned start Sep 2023; status: not yet recruiting.
02
Drugs
ersodetug
03
Conditions
congenital hyperinsulinism (HI)
Beyond the preview
Go deeper on MOH_2023-11-23_013070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-11-23_013070.